Epcoritamab is a subcutaneously IgG1-bispecific antibody redirecting CD3-positive T lymphocytes to CD20-positive B-cell lymphoma tissue. The gene discussed is MS4A1; the disease is B-cell non-Hodgkin lymphoma.